AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

19 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

23 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

22 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

24 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

02 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

21 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

07 Sep 2023 07:03:16 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire